Sensitization of Osteosarcoma Cell Line SaOS-2 to Chemotherapy by Downregulating Survivin

Archives of Medical Research

Volumn 41, Issue 3, 2010, Pages 162-169

  Zou, Jun ^a   Gan, Minfeng ^a   Mao, Nana ^b   Zhu, Xuesong ^a   Shi, Qin ^a   Yang, Huilin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Suzhou School of Medial Science and Technology   (China)

Author keywords

Chemotherapy; Osteosarcoma; Sensitization; Survivin

Indexed keywords

CASPASE 3; CISPLATIN; DOXORUBICIN; ETOPOSIDE; SHORT HAIRPIN RNA; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE DEPOLARIZATION; CELL VIABILITY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OSTEOSARCOMA; PROTEIN EXPRESSION; SENSITIZATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BONE NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROTUBULE-ASSOCIATED PROTEINS; OSTEOSARCOMA; RNA, SMALL INTERFERING;

EID: 77953527629     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.04.006     Document Type: Article

References (33)

1. Desandes E. Survival from adolescent cancer. Cancer Treat Rev 2007, 33:609-615.
2. Link M.P., Goorin A.M., Miser A.W., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986, 314:1600-1606.
3. Bacci G., Briccoli A., Ferrari S., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001, 37:2030-2039.
4. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
5. Lamoureux F., Richard P., Wittrant Y., et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007, 67:7308-7318.
6. Dass C.R., Choong P.F. Gene therapy for osteosarcoma: steps towards clinical studies. J Pharm Pharmacol 2008, 60:405-413.
7. Lamoureux F., Trichet V., Chipoy C., et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007, 7:169-181.
8. Yin D., Jia T., Gong W., et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol 2008, 33:253-259.
9. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006, 18:609-615.
10. Dohi T., Beltrami E., Wall N.R., et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004, 114:1117-1127.
11. Dohi T., Okada K., Xia F., et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004, 279:34087-34090.
12. Shin S., Sung B.J., Cho Y., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
13. Vong Q.P., Cao K., Li H.Y., et al. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 2005, 310:1499-1504.
14. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
15. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3:46-54.
16. Wang W., Luo H., Wang A. Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 2006, 93:578-584.
17. Osaka E., Suzuki T., Osaka S., et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 2006, 39:95-100.
18. Trieb K., Lehner R., Stulnig T., et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003, 29:379-382.
19. Liang X., Da M., Zhuang Z., et al. Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int 2009, 33:119-124.
20. Li Q.X., Zhao J., Liu J.Y., et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 2006, 5:860-866.
21. Ko S., Yuen W.F., Fung K.P., et al. Reversal of TNF-alpha resistance by hyperthermia: role of mitochondria. Life Sci 2000, 67:3113-3121.
22. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential in apoptosis; an update. Apoptosis 2003, 8:115-128.
23. Peñuelas S., Noé V., Ciudad C.J. Modulation of IMPDH2; survivin; topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J 2005, 72:696-710.
24. Olie R.A., Simões-Wüst A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000, 60:2805-2809.
25. Wang L., Zhang G.M., Feng Z.H. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line. Acta Pharmacol Sin 2003, 24:1235-1240.
26. Zhang W., Chen X., Qiu F. An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy. J Huazhong Univ Sci Technol Med Sci 2003, 23:387-391.
27. Hayashi N., Asano K., Suzuki H., et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 2005, 65:10-19.
28. Kojima H., Iida M., Yaguchi Y., et al. Enhancement of cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg 2006, 132:682-685.
29. Van Valen F., Fulda S., Schäfer K.L., et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer 2003, 107:929-940.
30. Lens S.M., Wolthuis R.M., Klompmaker R., et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003, 22:2934-2947.
31. Cassano W.F., Graham-Pole J., Dickson N. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 1991, 68:1899-1902.
32. Call J.A., Eckhardt S.G., Camidge D.R. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008, 9:1002-1011.
33. Mazumder S., Plesca D., Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol 2008, 414:13-21.